The prevalence and risk factors of rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis

Hong-Fei Wang,Yan-Yun Wang,Zhi-Yu Li,Pei-Jie He,Shan Liu,Qiu-Shuang Li

DOI: https://doi.org/10.1080/07853890.2024.2332406

IF: 5.348

2024-03-30

Annals of Medicine

Abstract:Background Interstitial lung disease (ILD) is the most widespread and fatal pulmonary complication of rheumatoid arthritis (RA). Existing knowledge on the prevalence and risk factors of rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is inconclusive. Therefore, we designed this review to address this gap.

medicine, general & internal

What problem does this paper attempt to address?

The problem this paper attempts to address is the prevalence and risk factors of rheumatoid arthritis-associated interstitial lung disease (RA-ILD). Specifically, the authors aim to summarize the prevalence of RA-ILD through a systematic review and meta-analysis and identify the risk factors associated with RA-ILD.

### Background
Interstitial lung disease (ILD) is one of the most common pulmonary complications of rheumatoid arthritis (RA), significantly impacting patient morbidity and mortality. Although studies have explored the prevalence and risk factors of RA-ILD, their results are inconsistent, necessitating further research to clarify these issues.

### Objectives
1. **Summarize the prevalence of RA-ILD**: Aggregate the prevalence of RA-ILD reported in different studies through a systematic review and meta-analysis.
2. **Identify risk factors for RA-ILD**: Determine which factors are associated with the occurrence of RA-ILD to better understand its pathogenesis, thereby promoting early diagnosis and management.

### Methods
- **Data Sources**: The authors searched relevant literature from multiple databases, including EMBase, Web of Science, PubMed, and the Cochrane Library.
- **Inclusion Criteria**: Observational studies (cohort studies, case-control studies, and cross-sectional studies) that recorded the prevalence or risk factors of RA-ILD were included.
- **Statistical Analysis**: Fixed-effect or random-effect models were used to estimate pooled odds ratios (ORs), hazard ratios (HRs), and weighted mean differences (WMDs). Subgroup analysis, meta-regression analysis, and sensitivity analysis were conducted to assess heterogeneity and publication bias.

### Results
- **Prevalence**: A total of 56 studies involving 11,851 RA-ILD patients were included. The pooled prevalence of RA-ILD was 18.7% (95% CI 15.8–21.6), with significant heterogeneity (I² = 96.4%).
- **Risk Factors**: Male gender, older age, smoking history, pulmonary comorbidities, older age at RA onset, longer RA duration, RF positivity, ACPA positivity, higher ESR, higher DAS28 score (≥3.2), presence of rheumatoid nodules, use of leflunomide, and use of glucocorticoids were significant risk factors for RA-ILD. The use of biologics was a protective factor.

### Conclusion
- **Prevalence**: The pooled prevalence of RA-ILD is approximately 18.7%.
- **Risk Factors**: Male gender, older age, smoking history, pulmonary comorbidities, older age at RA onset, longer RA duration, RF positivity, ACPA positivity, higher ESR, higher DAS28 score (≥3.2), presence of rheumatoid nodules, use of leflunomide, and use of glucocorticoids are major risk factors for RA-ILD. The use of biologics can reduce the risk of RA-ILD.

This study provides important reference points for the clinical management and prevention of RA-ILD.